z-logo
Premium
Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease
Author(s) -
Morris Claudia R.,
Kuypers Frans A.,
Larkin Sandra,
Sweeters Nancy,
Simon Julie,
Vichinsky Elliott P.,
Styles Lori A.
Publication year - 2000
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2000.02403.x
Subject(s) - nitric oxide , arginine , medicine , metabolite , vaso occlusive crisis , disease , limiting , sickle cell anemia , cell , gastroenterology , endocrinology , chemistry , biochemistry , amino acid , mechanical engineering , engineering
To determine the effects of l ‐arginine ( l ‐Arg) supplementation on nitric oxide metabolite (NO x ) production, oral l ‐Arg was given to normal controls, sickle cell disease (SCD) patients at steady state and SCD patients hospitalized with a vaso‐occlusive crisis (VOC). l ‐Arg (0·1 g/kg) increased NO x formation by 18·8 ± 68% in normal controls, whereas steady‐state SCD patients demonstrated a paradoxical decrease in NO x of −16·7 ± 4% ( P  = 0·004). In contrast, patients with VOC demonstrated a dramatic increase in NO x production by +77·7 ± 103%, a response that was dose dependent. l ‐Arg appears to be the rate‐limiting step in NO x production during VOC. Oral arginine may therefore benefit SCD patients by inducing an increase in NO production during VOC.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here